Bristol-Myers Squibb Company Ce Receivables

The latest receivables for CELG-RI is $2.4B as of September 2019. That compares with $2.1B in the prior-year period — up 12.0% year over year. Investors often review this figure alongside Bristol-Myers Squibb Company Ce's historical trend and sector peers before judging valuation or financial health.

Over the past year, CELG-RI's receivables moved from $2.1B to $2.4B — a 12.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb Company Ce's operating scale or balance-sheet position.

A receivables figure of $2.4B for CELG-RI is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CELG-RI's receivables ($2.4B), review year-over-year change from $2.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.